Agent for treating visual cell function disorder

Details Agent for treating visual cell function disorder Agent for treating visual cell function disorder

2005-03-08

2005-03-08

Tate, Christopher R. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S021800, C514S002600, C536S006500, C435S069500

Reexamination Certificate

active

06864232

ABSTRACT:
The present invention provides an agent for treating retinopathy containing a tricyclo compound of formula (I)

REFERENCES:
patent: 0 406 791 (1991-01-01), None
patent: 0 532 862 (1993-03-01), None
patent: 0 532 862 (1993-03-01), None
patent: 2 084 222 (1997-07-01), None
patent: WO 9203049 (1992-03-01), None
patent: WO 9413275 (1994-06-01), None
patent: WO 9600073 (1996-01-01), None
patent: WO 9900129 (1999-01-01), None
patent: WO 9934830 (1999-07-01), None
patent: WO 0009109 (2000-02-01), None
Morice et al. 1993, J. of Biol. Chem, vol. 268, No. 5, pp. 3734-3738.*
Ryffel et al. 1995, Immunopharmacology, vol. 30, pp. 199-207.*
Tsuboi et al. 1994, Molecular Biology of the Cell, vol. 5, pp. 119-128.*
Nussenblatt R.B., Uveitis in Behcet's Disease. Int. Rev. Immunol. 1997, vol. 14, No. 1, pp. 67-79.*
J. Kiryu, et al., Annual Meeting of the Association for Research in Vision and Ophthalmology, vol. 39, No. 4, p. S273, “In Vivo Evaluation of the Inhibitory Effects of Tacrolimus (FK506) on Leukocyte Accumulation During Retinal Ischemia Reperfusion Injury”, May 10-15, 1998.
M. Kikuchi, et al., Investigative Opthalmology and Visual Science, vol. 39, No. 7, pp. 1227-1232, “Protective Effects of FK506 Against Glutamate-Induced Neurotoxicity in Retinal Cell Culture”, Jun. 1998.
A. Tsujikawa, et al., Stroke, vol. 29, No. 7, pp. 1431-1438, “Tacrolimus (FK506) Attenuates Leukocyte Accumulation After Transient Retinal Ischemia”, 1998.
D. F. Martin, et al., The Journal of Immunology, vol. 154, No. 2, pp. 922-927. “Synergistic Effect of Rapamycin and Cyclosporin A in the Treatment of Experimental Autoimmune Uveoretinitis”, 1995.
P. A. Pearson, et al., Investigative Ophthalmology & Visual Science, Annual Meeting of the Association for Research in Vision and Ophthalmology, vol. 35, No. 4, p. 1923, “Sustained Delivery of Cyclosporine (CsA) and Dexamethasone (DEX) in the Treatment of Experimental Proliferative Vitreoretinopathy”, May 1-6, 1994.
G. Striph, et al., Arch. Ophthalmol., vol. 104, No. 1, pp. 114-117, “Retina S Antigen-Induced Uveitis. The Efficacy of Cyclosporine and Corticosteriods in Treatment”, Jan. 1986.
M. Ishioka, et al.,American Journal of Ophthalmology, vol. 118, pp. 723-729 (Dec. 1994).
D.A. Harkevich “Pharmacology”, Moscow, “Meditsina”, 1987, pp. 47-48.
“Opthamalic Diseases” by Prof. V.G. Kopaeva, M. “Meditsina”, 2002, pp. 303-336.
U.S. Appl. No. 10/495,425, filed May 21, 2004, Ueno.
U.S. Appl. No. 09/869,129, filed Jun. 25, 2001, Ueno.

Affiliated with

Also associated with

Rating

Agent for treating visual cell function disorder does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Agent for treating visual cell function disorder, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agent for treating visual cell function disorder will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3388193